Page last updated: 2024-08-23

raloxifene hydrochloride and Metastase

raloxifene hydrochloride has been researched along with Metastase in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (25.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Bruns, CJ; Camaj, P; Hartmann, L; Hering, NA; Kreis, ME; Lee, LD; Liu, V; Müller, MH; Pozios, I; Seel, NN; Seeliger, H	1
Flamini, MI; Fu, XD; Garibaldi, S; Genazzani, AR; Giretti, MS; Goglia, L; Pisaneschi, S; Sanchez, AM; Simoncini, T; Tosi, V	1
Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G	1
Buzdar, AU; Holmes, F; Hortobagyi, G; Hug, V; Marcus, C	1

Reviews

1 review(s) available for raloxifene hydrochloride and Metastase

Article	Year
[Antiestrogen therapy in the treatment of breast neoplasms]. Minerva ginecologica, 2002, Volume: 54, Issue:3 Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Forecasting; Humans; Indoles; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles	2002

Article

Year

[Antiestrogen therapy in the treatment of breast neoplasms].

Minerva ginecologica, 2002, Volume: 54, Issue:3

Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Forecasting; Humans; Indoles; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles

2002

Other Studies

3 other study(ies) available for raloxifene hydrochloride and Metastase

Article	Year
Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. Cellular oncology (Dordrecht), 2021, Volume: 44, Issue:1 Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Cytokine Receptor gp130; Estrogen Receptor beta; Humans; Interleukin-6; Male; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Raloxifene Hydrochloride; Signal Transduction; STAT3 Transcription Factor; Time Factors; Xenograft Model Antitumor Assays	2021
Effects of raloxifene on breast cancer cell migration and invasion through the actin cytoskeleton. Journal of cellular and molecular medicine, 2009, Volume: 13, Issue:8B Topics: Actins; Breast Neoplasms; Cell Line, Tumor; Cytoskeleton; Female; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Raloxifene Hydrochloride	2009
Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology, 1988, Volume: 45, Issue:5 Topics: Breast Neoplasms; Drug Evaluation; Estrogen Antagonists; Female; Humans; Neoplasm Metastasis; Piperidines; Raloxifene Hydrochloride	1988